Biohaven has entered into a licensing and collaboration agreement with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio in select Asian territories, securing up to $100 million in near-term payments and 20% royalties on net sales. This deal provides Biohaven with significant non-dilutive funding and expands the global reach of its drug candidates, particularly BHV-1300 for Graves' disease.
Biohaven (BHVN) has announced a strategic licensing and collaboration agreement with Ono Pharmaceutical, granting Ono exclusive rights to develop and commercialize Biohaven's MoDE pan IgG degrader portfolio in Japan, South Korea, Taiwan, and ASEAN countries. This deal is significant as it provides Biohaven with an immediate financial injection of $80 million upfront and a potential $20 million milestone payment, along with 20% royalties on future net sales, bolstering its financial position. For traders, this represents a positive catalyst for BHVN, as it validates its platform technology and provides non-dilutive funding for ongoing development, potentially reducing future capital raise needs. The long-term implication is expanded market access for its drug candidates, particularly BHV-1300, which is in Phase 3 for Graves' disease and has potential for other autoimmune conditions. The previous deal with SK Biopharmaceuticals is mentioned for context but does not directly impact this new agreement.